OMRF’s scientists, who include a member of the National Academy of Sciences, hold more than 700 U.S. and international patents and have spun off 11 biotech companies. Discoveries at OMRF led to Xigris, the first FDA-approved drug for the treatment of severe sepsis, and Ceprotin, a therapy for people suffering from a rare and life-threatening blood disorder known as protein C deficiency. Research at OMRF also identified the enzyme believed responsible for Alzheimer’s disease and laid the groundwork for OncoVue, a breast cancer risk assessment test.